Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.0
Trade Value (12mth)
N/A
1 week
-5.26%
1 month
-5.26%
YTD
-14.29%
1 year
0%
All time high
N/A
EPS 3 yr Growth
N/A
EBITDA Margin
N/A
Operating Cashflow
N/A
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
N/A
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
N/A
Short Sell (% of issue)
N/A
Date | Announcements |
---|---|
31 August 23 |
Appendix 4E and Preliminary Financial Report
×
Appendix 4E and Preliminary Financial Report |
30 October 23 |
Quarterly activities and cashflow report
×
Quarterly activities and cashflow report |
27 September 23 |
Annual Report to shareholders
×
Annual Report to shareholders |
27 September 23 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
27 October 23 |
Restricted securities to be released from escrow
×
Restricted securities to be released from escrow |
22 September 23 |
Notice Required Under ASX Listing Rule 3.13.1
×
Notice Required Under ASX Listing Rule 3.13.1 |
22 November 23 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
21 September 23 |
Change of Registry Address
×
Change of Registry Address |
19 September 23 |
Application for quotation of securities - COV
×
Application for quotation of securities - COV |
13 October 23 |
Application for quotation of securities - COV
×
Application for quotation of securities - COV |
12 September 23 |
Restricted securities to be released from escrow
×
Restricted securities to be released from escrow |
09 October 23 |
Cleo Delivers Early Progress on Development Program
×
Cleo Delivers Early Progress on Development Program |
06 October 23 |
Restricted securities to be released from escrow
×
Restricted securities to be released from escrow |
06 November 23 |
Completion of First Triage Test Clinical Validation Study
×
Completion of First Triage Test Clinical Validation Study |
06 November 23 |
Application for quotation of securities - COV
×
Application for quotation of securities - COV |
05 October 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
05 October 23 |
Letter to Shareholders
×
Letter to Shareholders |
03 November 23 |
Pause in Trading
×
Pause in Trading |
03 November 23 |
Trading Halt
×
Trading Halt |
02 October 23 |
Cleo Enhances Board Capacity
×
Cleo Enhances Board Capacity |
01 September 23 |
Letter from the CEO to Shareholders
×
Letter from the CEO to Shareholders |
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.